Somerset Files Response to EMSAM(R) Action Letter

FDA Considers Response Complete - Issues PDUFA Review Date

PITTSBURGH and CORONA, Calif., June 16 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) and Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that Somerset Pharmaceuticals, Inc. has submitted a response to the United States Food and Drug Administration's Action letter, dated January 30, 2004, related to EMSAM® (selegiline transdermal system). The FDA has accepted Somerset's May 26, 2005 response as complete and has issued a Prescription Drug User Fee Act (PDUFA) goal date for these submissions of November 27, 2005.

Somerset Pharmaceuticals, Inc. is a joint venture between Mylan and Watson. EMSAM® is an investigational monoamine oxidase inhibitor administered transdermally for acute and maintenance treatment of patients with major depressive disorder.

About Mylan Laboratories Inc.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com.

Forward-looking statements

The parties caution that this press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual future results may differ materially from those expressed or implied by such forward-looking statements due to such factors including, but not limited to, unexpected regulatory or other delays; delays or extensions of the PDUFA date, uncertainties beyond the control of management, and other risks detailed from time to time in the Securities and Exchange Commission filings of Mylan Laboratories Inc. and Watson Pharmaceuticals, Inc. Except as required by law, the parties undertake no obligation to update these statements for revisions or changes after the date of this release.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)

SOURCE Watson Pharmaceuticals, Inc.; Mylan Laboratories Inc.
06/16/2005
CONTACT: Patrick Fitzgerald (Media), +1-724-514-1800, patrick.fitzgerald@mylanlabs.com, or Kris King (Investors), +1-724-514-1800, kris.king@mylanlabs.com, both of Mylan Laboratories Inc.; or Patty Eisenhaur (Media & Investors), Watson Pharmaceuticals, Inc., +1-951-493-5611, peisenhaur@watsonpharm.com
Web site: http://www.mylan.com
Web site: http://www.watsonpharm.com